Charles Schwab Investment Management Inc. Grows Stock Position in Biohaven Ltd. (NYSE:BHVN)

Charles Schwab Investment Management Inc. grew its holdings in shares of Biohaven Ltd. (NYSE:BHVN) by 5.5% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 632,690 shares of the company’s stock after purchasing an additional 32,769 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.67% of Biohaven worth $31,616,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. nVerses Capital LLC purchased a new stake in shares of Biohaven during the 3rd quarter valued at about $50,000. Redwood Wealth Management Group LLC purchased a new stake in Biohaven in the 2nd quarter worth approximately $61,000. Values First Advisors Inc. purchased a new stake in Biohaven in the 3rd quarter worth approximately $78,000. US Bancorp DE increased its holdings in Biohaven by 57.1% in the 3rd quarter. US Bancorp DE now owns 2,173 shares of the company’s stock worth $109,000 after acquiring an additional 790 shares in the last quarter. Finally, KBC Group NV increased its holdings in Biohaven by 24.5% in the 3rd quarter. KBC Group NV now owns 2,250 shares of the company’s stock worth $112,000 after acquiring an additional 443 shares in the last quarter. Hedge funds and other institutional investors own 88.78% of the company’s stock.

Biohaven Trading Down 2.4 %

Shares of BHVN opened at $43.68 on Wednesday. The firm has a market capitalization of $4.42 billion, a P/E ratio of -4.67 and a beta of 1.24. Biohaven Ltd. has a 12-month low of $26.80 and a 12-month high of $62.21. The firm has a fifty day moving average price of $49.74 and a 200-day moving average price of $41.47.

Biohaven (NYSE:BHVN) last issued its earnings results on Tuesday, November 12th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.03). Analysts predict that Biohaven Ltd. will post -8.85 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Gregory Bailey acquired 5,000 shares of the business’s stock in a transaction dated Tuesday, September 24th. The shares were purchased at an average price of $44.19 per share, for a total transaction of $220,950.00. Following the completion of the acquisition, the director now directly owns 1,620,071 shares in the company, valued at $71,590,937.49. The trade was a 0.31 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director John W. Childs acquired 21,052 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The shares were bought at an average price of $47.50 per share, for a total transaction of $999,970.00. Following the acquisition, the director now owns 21,052 shares of the company’s stock, valued at approximately $999,970. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. 16.00% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on BHVN shares. Bank of America increased their target price on shares of Biohaven from $52.00 to $62.00 and gave the stock a “buy” rating in a report on Tuesday, September 24th. Leerink Partners increased their target price on Biohaven from $55.00 to $60.00 and gave the company an “outperform” rating in a research report on Monday, September 23rd. Robert W. Baird increased their target price on Biohaven from $58.00 to $60.00 and gave the company an “outperform” rating in a research report on Monday, September 23rd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Biohaven in a research report on Wednesday, October 23rd. Finally, JPMorgan Chase & Co. increased their target price on Biohaven from $55.00 to $68.00 and gave the company an “overweight” rating in a research report on Thursday, October 3rd. Thirteen research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Biohaven presently has an average rating of “Buy” and a consensus target price of $62.75.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.